Skip Navigation



Rheumatology Advance Access published online on October 27, 2004
Rheumatology, doi:10.1093/rheumatology/keh449
Rheumatology © British Society for Rheumatology 2004; all rights reserved
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/2/192    most recent
keh449v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Satoh, T.
Right arrow Articles by Kuwana, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Satoh, T.
Right arrow Articles by Kuwana, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received July 11, 2004
Accepted September 21, 2004

Concise Report

Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension

T. Satoh 1, K. Kimura 2, Y. Okano 3, M. Hirakata 4, Y. Kawakami , and M. Kuwana 2*

1 Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan; Department of Laboratory Medicine, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
2 Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
3 Okano Clinic, Abiko, Japan
4 Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

* To whom correspondence should be addressed.
M. Kuwana, E-mail: kuwanam{at}sc.itc.keio.ac.jp


  Abstract

Objectives. To examine whether autoantibodies against bone morphogenetic protein receptor-II (BMPR-II) or activin receptor-like kinase 1 (ALK-1) are associated with pulmonary arterial hypertension (PAH) in patients with mixed connective tissue disease (MCTD).

Methods. We studied sera from 37 MCTD patients with or without PAH, six patients with idiopathic PAH, and 30 healthy controls. Circulating anti-BMPR-II and anti-ALK-1 antibodies were detected using immunoprecipitation of recombinant antigens generated by in vitro transcription/translation and indirect immunofluorescence of cultured cells that were induced to express these antigens by gene transfer. Anti-BMPR-II antibodies were further examined by immunoprecipitation and immunoblotting using a recombinant fragment of the extracellular domain of BMPR-II.

Results. Serum anti-BMPR-II and anti-ALK-1 autoantibodies were not detected in MCTD patients irrespective of the presence or absence of PAH, or in patients with idiopathic PAH.

Conclusions. Our finding does not support the hypothesis that autoantibody-mediated dysregulation of signals through BMPR-II or ALK-1 contributes to the development of PAH in patients with connective tissue diseases.

Keywords: Pulmonary arterial hypertension; Autoantibody; Mixed connective tissue disease; Bone morphogenetic protein receptor-II; Activin receptor-like kinase 1.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Child Health CareHome page
J. E. McDonagh, K. L. Shaw, and T. R. Southwood
Growing up and moving on in rheumatology: development and preliminary evaluation of a transitional care programme for a multicentre cohort of adolescents with juvenile idiopathic arthritis
J Child Health Care, March 1, 2006; 10(1): 22 - 42.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.